Gene therapy platform with three shots on goal, but AAV2-hAQP1's pivotal readout is the fulcrum: Phase 2 data either opens a clear BLA path or leaves bota-vec's contested filing carrying the entire near-term case

MeiraGTx is an early-stage gene therapy company developing three programs, with its lead candidate a gene therapy for radiation-induced dry mouth that is not yet approved.

MeiraGTx has rebuilt itself around three distinct gene therapy programs after acquiring bota-vec from J&J following a Phase 3 primary endpoint miss, funding the pivot with $400M from Oberland Capital on largely non-dilutive terms. AAV2-hAQP1, a salivary-gland gene therapy for radiation-induced dry mouth backed by Breakthrough Therapy Designation and three-year Phase 1 durability data, resolves on whether Phase 2 pivotal data support a BLA. Bota-vec's approvability on secondary-endpoint data alone, without a met primary endpoint, represents an unconventional regulatory path that FDA has not yet validated.